½Å½ÅÆÄ½º¿¡½º¼ÒÇü SINSINPAS-S Small Size
ÀϹÝÀǾàǰ | ºñ±Þ¿©
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
ÀϹÝ
»ì»ö ¶Ç´Â ¹ÌȲ»öÀÇ ¸éÆ÷¿¡ ¾àǰÀ» ÀüÆ÷ÇÑ °ÍÀ¸·Î Ç¥¸é¿¡´Â ¿øÇü ¶Ç´Â ÀÏÀÚÇü ±â°øÀÌ ÀÖ°í ÇǺο¡ ºÎÂøÇϱ⠽±´Ù.
Á¦Á¶È¸»ç
½Å½ÅÁ¦¾à(ÁÖ)
ÆÇ¸Åȸ»ç
½Å½ÅÁ¦¾à(ÁÖ)
Çã°¡Á¤º¸
Á¤»ó
(1989.05.09)
BIT ¾àÈ¿ºÐ·ù
¿Ü¿ë ¼Ò¿°ÁøÅëÁ¦ (NSAIDs : Skin & Mucous Membrane)
º¹ÁöºÎºÐ·ù
264[ÁøÅ롤Áø¾ç¡¤¼ö·Å¡¤¼Ò¿°Á¦ ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
643800480 [ºñ±Þ¿©]
ATCÄÚµå
Preparations with salicylic acid derivatives / M02AC
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
±Û¸®¼¼¸±·ÎÁö³×ÀÌÆ® ,
¸°Æ®Æ÷ ,
¸°Æ®Æ÷(¼öÃâ¿ë) ,
ºÎÆ¿È÷µå·Ï½ÃÅç·ç¿£ ,
»êȾƿ¬ ,
¾ÆÅ©¸±»êÀüºÐ ,
õ¿¬°í¹« ,
ħ°Åº»êÄ®½· ,
ÅÚÇÉ·¹Áø(ÄýÅæ) ,
ÅÚÇÉ·¹Áø(YS·¹Áø) ,
Æú¸®ºÎÅÙ ,
Æú¸®¿¡Æ¿·»Çʸ§ ,
Æú¸®ÀÌ¼ÒºÎÆ¿·» ,
ÈÒÆ¼À̽º
Á¦Ç°º° ¿¬·É±Ý±â °í½Ã
¼ººÐ¸í
¼ººÐÄÚµå
ƯÁ¤¿¬·É
°í½Ã¹øÈ£
°í½ÃÀÏÀÚ
ºñ°í
L-menthol
C85700CPL
30 °³¿ù ÀÌÇÏ
20250046
2025-07-14
¼Ò¾Æ¿¡¼ °æ·ÃÀ» À¯¹ßÇÒ ¼ö ÀÖÀ½
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
643800480
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
»ì»ö ¶Ç´Â ¹ÌȲ»öÀÇ ¸éÆ÷¿¡ ¾àǰÀ» ÀüÆ÷ÇÑ °ÍÀ¸·Î Ç¥¸é¿¡´Â ¿øÇü ¶Ç´Â ÀÏÀÚÇü ±â°øÀÌ ÀÖ°í ÇǺο¡ ºÎÂøÇϱ⠽±´Ù.
[Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
1¸Å (8.9¡¿11.9§²) : ¨ç6¸Å / Æ÷, ¨è14¸Å / Æ÷ , ¨é60¸Å / 10 Æ÷ / ÄÉÀ̽º 1¸Å (8.9¡¿5.95§²) : ¨ç8¸Å / Æ÷, ¨è80¸Å / 10Æ÷ / ÄÉÀ̽º 1¸Å
Æ÷À塤ÄÚµå´ÜÀ§
¾àǰ±Ô°Ý
´ÜÀ§
´ëÇ¥ÄÚµå
Ç¥ÁØÄÚµå
ºñ°í
15.08¹Ð¸®±×·¥
1 ¸Å
8806438004809
8806438004878
(6.2*4.1)§²
15.08¹Ð¸®±×·¥
14 ¸Å
8806438004809
8806438004861
(6.2*4.1)§²
15.08¹Ð¸®±×·¥
12 ¸Å
8806438004809
8806438004854
(6.2*4.1)§²
15.08¹Ð¸®±×·¥
10 ¸Å
8806438004809
8806438004847
(6.2*4.1)§²
15.08¹Ð¸®±×·¥
20 ¸Å
8806438004809
8806438004830
(6.2*4.1)§²
15.08¹Ð¸®±×·¥
80 ¸Å
8806438004809
8806438004823
(6.2*4.1)§²
15.08¹Ð¸®±×·¥
40 ¸Å
8806438004809
8806438004816
(6.2*4.1)§²
ÁÖ¼ººÐÄÚµå
C85700CPL
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
º¸°ü¹æ¹ý
¹ÐÆó¿ë±â, ½Ç¿Âº¸°ü
¾à¸®ÀÛ¿ë
[Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ Áõ»óÀÇ ÁøÅë ¡¤ ¼Ò¿°£¨Ç׿°£© : »ã , Ÿ¹Ú»ó£¬ ±ÙÀ°Å룬 °üÀýÅ룬 °ñÀýÅ룬 ¿ä£¨Ç㸮£©Å룬 ¾î±ú°á¸² , ½Å°æÅ룬 ·ù¸¶Æ¼½ºÅëÁõ
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1ÀÏ 1,2ȸ ȯºÎ£¨Áúȯ ºÎÀ§£©¿¡ ºÙÀδ٣®
±Ý±â
1) 30 °³¿ù ÀÌÇÏÀÇ À¯¾Æ
2) ½ÀÁø£¬ ¿Ì µî¿¡ ÀÇÇÑ ÇǺο° , »óóºÎÀ§
½ÅÁßÅõ¿©
1) Áö±Ý±îÁö ¾àÀ̳ª ÈÀåǰ µî¿¡ ÀÇÇÑ ¾Ë·¹¸£±â Áõ»ó£¨¿¹¸¦ µé¸é ¹ßÁø ¡¤ ¹ßÀû£¨ÃæÇ÷µÇ¾î ºÓ¾îÁü£©, °¡·Á¿ò£¬ ¿Ì µî¿¡ ÀÇÇÑ ÇǺο° µî£©ÀÌ ³ªÅ¸³ ÀûÀÌ Àִ ȯÀÚ
2) º»ÀÎ ¶Ç´Â °¡Á·ÀÌ ¾Ë·¹¸£±â üÁúÀΠȯÀÚ
3) ½ÀÀ±£¨½À±â Âü£©À̳ª ¹Ì¶õ£¨Áþ¹«¸§£©ÀÌ ½ÉÇÑ È¯ÀÚ
4) ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í Àִ ȯÀÚ
5) ¼Ò¾Æ£¨°æ·ÃÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù£©
6) ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ¿©¼º
7) ¼öÀ¯ºÎ
ÀÌ»ó¹ÝÀÀ
ÀÌ ¾àÀÇ »ç¿ëÀ¸·Î ¹ßÁø ¡¤ ¹ßÀû£¨ÃæÇ÷µÇ¾î ºÓ¾îÁü£©, °¡·Á¿ò µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù£®
ÀϹÝÀû ÁÖÀÇ
1) Á¤ÇØÁø ¿ë¹ý ¡¤ ¿ë·®À» Àß ÁöŲ´Ù£® '
2) ¼Ò¾Æ¿¡°Ô »ç¿ëÇÒ °æ¿ì¿¡´Â º¸È£ÀÚÀÇ Áöµµ ¡¤ °¨µ¶ÇÏ¿¡ »ç¿ëÇÑ´Ù£®
3) 5,6 Àϰ£ Åõ¿© ÈÄ¿¡µµ Áõ»óÀÇ °³¼±ÀÌ º¸ÀÌÁö ¾ÊÀ» °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù£®
4) »ì¸®½Ç»ê¸ÞÆ¿Àº ÇǺθ¦ ÅëÇÏ¿© ¸¹Àº ¾çÀÌ Èí¼öµÉ °æ¿ì Áßµ¶Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ³ÐÀº Ç¥¸é¿¡ ´ëÇÑ Àå±â°£ÀÇ »ç¿ëÀº ÇÇÇÑ´Ù.
Àû¿ë»óÀÇ ÁÖÀÇ
ÀÌ ¾àÀº ¿Ü¿ëÀ¸·Î¸¸ »ç¿ëÇÑ´Ù£®
º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ
1) ¾î¸°ÀÌÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇÑ´Ù.
2) Á÷»çÀϱ¤À» ÇÇÇÏ°í µÉ ¼ö ÀÖÀ¸¸é ½À±â°¡ Àû°í ¼´ÃÇÑ °÷¿¡ ¹ÐÀüÇÏ¿©£¨¶Ñ²±À» ²À ´Ý¾Æ£© º¸°üÇÑ´Ù£®
3) ¿À¿ë£¨À߸ø »ç¿ë£©À» ¸·°í ǰÁúÀÇ Ç°ÁúÀÇ º¸Á¸À» À§ÇÏ¿© ´Ù¸¥ ¿ë±â¿¡ ¹Ù²Ù¾î ³ÖÁö ¾Ê´Â´Ù
Related FDA Approved Drug
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
643800480
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
Á¦Ç°¼º»ó
»ì»ö ¶Ç´Â ¹ÌȲ»öÀÇ ¸éÆ÷¿¡ ¾àǰÀ» ÀüÆ÷ÇÑ °ÍÀ¸·Î Ç¥¸é¿¡´Â ¿øÇü ¶Ç´Â ÀÏÀÚÇü ±â°øÀÌ ÀÖ°í ÇǺο¡ ºÎÂøÇϱ⠽±´Ù.
[Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
1¸Å (8.9¡¿11.9§²) : ¨ç6¸Å / Æ÷, ¨è14¸Å / Æ÷ , ¨é60¸Å / 10 Æ÷ / ÄÉÀ̽º 1¸Å (8.9¡¿5.95§²) : ¨ç8¸Å / Æ÷, ¨è80¸Å / 10Æ÷ / ÄÉÀ̽º 1¸Å
º¸°ü¹æ¹ý
¹ÐÆó¿ë±â, ½Ç¿Âº¸°ü
º¹¾àÁ¤º¸
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
µ¶¼ºÁ¤º¸
Camphor ¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Diphenhydramine ¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
L-Menthol ¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do
Mechanism of Action
Diphenhydramine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Diphenhydramine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.
Pharmacology
Diphenhydramine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Diphenhydramine is an antihistamine of the ethanolamine class. Ethanolamine antihistamines have significant antimuscarinic activity and produce marked sedation in most patients. In addition to the usual allergic symptoms, the drug also treats irritant cough and nausea, vomiting, and vertigo associated with motion sickness. It also is used commonly to treat drug-induced extrapyramidal symptoms as well as to treat mild cases of Parkinson's disease. Rather than preventing the release of histamine, as do cromolyn and nedocromil, diphenhydramine competes with free histamine for binding at HA-receptor sites. Diphenhydramine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Ethanolamine derivatives have greater anticholinergic activity than do other antihistamines, which probably accounts for the antidyskinetic action of diphenhydramine. This anticholinergic action appears to be due to a central antimuscarinic effect, which also may be responsible for its antiemetic effects, although the exact mechanism is unknown.
Metabolism
Diphenhydramine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2D6 (CYP2D6)Cytochrome P450 3A4 (CYP3A4)
Protein Binding
Diphenhydramine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 98 to 99%
Half-life
Diphenhydramine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1-4 hours
Absorption
Diphenhydramine¿¡ ´ëÇÑ Absorption Á¤º¸ Quickly absorbed with maximum activity occurring in approximately one hour.
Pharmacokinetics
Methyl SalicylateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
Èí¼ö :
À§Àå°üÀ¸·ÎºÎÅÍ Àß Èí¼öµÈ´Ù.
¹þ°ÜÁø ÇǺθ¦ ÅëÇØ¼µµ Èí¼öµÉ ¼ö ÀÖ´Ù.
L-mentholÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
¼Ò½Ç : Èí¼öµÈ ¾à¹°Àº glucuronide Æ÷ÇÕü·Î¼ ¼Òº¯ ¹× ´ãÁóÀ» ÅëÇØ ¹è¼³µÈ´Ù.
DiphenhydramineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
ÃÖ°í ÁøÁ¤ È¿°ú : 1-3 ½Ã°£
ÀÛ¿ëÁö¼Ó½Ã°£ : 4-7 ½Ã°£
Èí¼ö : ÃÊȸÅë°úÈ¿°ú°¡ ÀÖ¾î¼ 40 - 60 % Á¤µµ°¡ Àü½Å¼øÈ¯À¸·Î µé¾î°¨
´ë»ç : ´ëºÎºÐ °£´ë»ç, ÀϺδ Æó¿Í ½ÅÀå¿¡¼µµ ´ë»ç
´Ü¹é°áÇÕ : 78%
ÃÖ°íÇ÷Áß³óµµ µµ´Þ½Ã°£ : 2-4 ½Ã°£
Tocopherol AcetateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
Èí¼ö : °æ±¸ :
¼ÒÀåÀ¸·ÎºÎÅÍ Èí¼öµÇ´Â µ¥¿¡´Â ´ãÁóÀÌ ÇÊ¿äÇÏ´Ù.
Èí¼ö ÀúÇÏ : Èí¼öÀå¾Ö ȯÀÚ, ÀúüÁß ¹Ì¼÷¾Æ, °í¿ë·® Åõ¿©
À¯ÈÁ¦Á¦º¸´Ù ¼ö¿ë¼º Á¦Á¦°¡ ´õ Àß Èí¼öµÈ´Ù.
ºÐÆ÷ : ¸ðµç Á¶Á÷¿¡ ºÐÆ÷Çϸç, ƯÈ÷ Áö¹æÁ¶Á÷¿¡ °í³óµµ·Î ºÐÆ÷Çϰí ÀúÀåµÈ´Ù.
´ë»ç : °£¿¡¼ glucuronides Æ÷ÇÕ
¼Ò½Ç : ÁÖ·Î ´ãÁóÀ» ÅëÇØ (70-80%) ¹è¼³µÈ´Ù.
Biotransformation
Diphenhydramine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic and renal
Toxicity
Diphenhydramine¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50 =500 mg/kg (orally in rats). Considerable overdosage can lead to myocardial infarction (heart attack), serious ventricular dysrhythmias, coma and death.
Drug Interactions
Diphenhydramine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Atomoxetine The CYP2D6 inhibitor could increases the effect and toxicity of atomoxetineDonepezil Possible antagonism of actionGalantamine Possible antagonism of actionMesoridazine Increased risk of cardiotoxicity and arrhythmiasRivastigmine Possible antagonism of actionThioridazine Increased risk of cardiotoxicity and arrhythmias
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
Food Interaction
Diphenhydramine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take with food.
Drug Target
[Drug Target]
Description
Camphor¿¡ ´ëÇÑ Description Á¤º¸ A bicyclic monoterpene ketone found widely in plants, especially cinnamomum camphora. It is used topically as a skin antipruritic and as an anti-infective agent. [PubChem]Diphenhydramine¿¡ ´ëÇÑ Description Á¤º¸ A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
Dosage Form
Diphenhydramine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralCream TopicalElixir OralLiquid IntramuscularLiquid IntravenousLiquid OralLozenge OralStrip OralSyrup OralTablet OralTablet, chewable Oral
Drug Category
Camphor¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Infective Agents, LocalDiphenhydramine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AnestheticsAnesthetics, LocalAnti-Allergic AgentsAntidyskineticsAntiemeticsAntiparkinson AgentsAntipruriticsAntitussivesEthanolamine DerivativesHistamine H1 AntagonistsHypnotics and Sedatives
Smiles String Canonical
Camphor¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1(C)C2CCC1(C)C(=O)C2Diphenhydramine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
Smiles String Isomeric
Camphor¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1(C)[C@H]2CC[C@]1(C)C(=O)C2Diphenhydramine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
InChI Identifier
Camphor¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3Diphenhydramine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
Chemical IUPAC Name
Camphor¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1,7,7-trimethylbicyclo[2.2.1]heptan-2-oneDiphenhydramine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-[di(phenyl)methoxy]-N,N-dimethylethanamine
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-08-27
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ